2-[4-Chloro-3-(trifluoromethyl)phenyl]-5-methyl-1,3-benzoxazole | 820240-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-Chloro-3-(trifluoromethyl)phenyl]-5-methyl-1,3-benzoxazole
• CAS: 820240-98-0
• 化学式: C₁₅H₉ClF₃NO
• 分子量: 311.68
• InChiKey: DXVLAFPRDZSPMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Immunosuppressant compounds and compositions
  申请人：Mi Yuan

  公开号：US20050014725A1

  公开（公告）日：2005-01-20

  The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

  本发明涉及免疫抑制剂、其生产过程、它们的用途以及含有它们的制药组合物。本发明提供了一种新的化合物类，可用于治疗或预防由淋巴细胞相互作用介导的疾病或障碍，特别是与EDG受体介导的信号转导有关的疾病。
• IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS
  申请人：Mi Yuan

  公开号：US20090131400A1

  公开（公告）日：2009-05-21

  The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

  本发明涉及免疫抑制剂、其生产过程、其用途以及包含它们的药物组合物。该发明提供了一种新的化合物类别，可用于治疗或预防由淋巴细胞相互作用介导的疾病或紊乱，特别是与EDG受体介导的信号转导有关的疾病。
• US7417065B2
  申请人：——

  公开号：US7417065B2

  公开（公告）日：2008-08-26
• US7750021B2
  申请人：——

  公开号：US7750021B2

  公开（公告）日：2010-07-06
• [EN] IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSES IMMUNOSUPPRESSEURS ET COMPOSITIONS
  申请人：IRM LLC

  公开号：WO2005000833A1

  公开（公告）日：2005-01-06

  The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.